Recursion Pharmaceuticals Inc (RXRX)
8.59
-0.20
(-2.28%)
USD |
NASDAQ |
May 08, 16:00
8.65
+0.06
(+0.70%)
After-Hours: 20:00
Recursion Pharmaceuticals Net Income (Annual): -328.07M for Dec. 31, 2023
Net Income (Annual) Chart
Historical Net Income (Annual) Data
Date | Value |
---|---|
December 31, 2023 | -328.07M |
December 31, 2022 | -239.48M |
December 31, 2021 | -186.48M |
Date | Value |
---|---|
December 31, 2020 | -87.01M |
December 31, 2019 | -61.88M |
Net Income Definition
Net Income is the total amount of profit earned by a company. This metric boils down to the overall profit that is left from the revenue that a company receives after taking out various operational line items like cost of goods sold, income tax expense, SG&A expense, etc. Eventually, all companies would want to have a consistent positive and growing net income, so that this can be used for various purposes like reinvesting into the company, paying off debt, and potentially paying out dividends to shareholders.
Net Income (Annual) Range, Past 5 Years
-328.07M
Minimum
2023
-61.88M
Maximum
2019
-180.58M
Average
-186.48M
Median
2021
Net Income (Annual) Benchmarks
Eli Lilly and Co | 5.240B |
Palatin Technologies Inc | -27.54M |
Oragenics Inc | -20.66M |
Actinium Pharmaceuticals Inc | -48.82M |
Marinus Pharmaceuticals Inc | -141.40M |